Hospital Mater Dei SA
BOVESPA:MATD3
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.48
4.95
|
| Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Hospital Mater Dei SA
Hospital Mater Dei SA engages in the provision of health care services. The company is headquartered in Belo Horizonte, Minas Gerais. The company went IPO on 2021-04-16. The firm has hospital beds distributed in its four units strategically located in the metropolitan region of Belo Horizonte and in Belem, in addition to hospital beds in the Hospital de Salvador/BA, Hospital Santa Genoveva in Uberlandia/MG, Hospital Premium in Goiania/GO and Hospital EMEC in Feira de Santana/BA. The firm provides services to several independent and self-managed health plan operators, such as: Allianz, Amil, Bacen, Bradesco Saude, Caixa Economica Federal, Care Plus, Cassi, Copass, FCA Saude, Golden Cross, IPSM, Sul America, Vale, among many others.
Hospital Mater Dei SA engages in the provision of health care services. The company is headquartered in Belo Horizonte, Minas Gerais. The company went IPO on 2021-04-16. The firm has hospital beds distributed in its four units strategically located in the metropolitan region of Belo Horizonte and in Belem, in addition to hospital beds in the Hospital de Salvador/BA, Hospital Santa Genoveva in Uberlandia/MG, Hospital Premium in Goiania/GO and Hospital EMEC in Feira de Santana/BA. The firm provides services to several independent and self-managed health plan operators, such as: Allianz, Amil, Bacen, Bradesco Saude, Caixa Economica Federal, Care Plus, Cassi, Copass, FCA Saude, Golden Cross, IPSM, Sul America, Vale, among many others.
Record Revenue: Mater Dei surpassed BRL 500 million in quarterly revenue for the first time, reaching BRL 546 million, driven by improved procedure mix and operational efficiency.
EBITDA Growth: EBITDA rose to BRL 150 million, up 32% from Q2 2024, with EBITDA margin increasing to 21.1%.
Occupancy & Productivity: Hospital occupancy hit 83%, maintained without adding significant new beds, reflecting higher operational productivity.
Cost Control: Cost ratios fell below 70% of revenue, and operational expenses dropped to 14.1%, aided by staff resizing and administrative streamlining.
Cash Generation & Debt: Net debt fell by BRL 35 million, leverage remained healthy at 1.6x, and favorable debt refinancing reduced rates by 50 bps.
Unit Ramp-Up: Salvador and Nova Lima hospitals posted strong revenue and patient growth, with Salvador’s net revenue up 25% and oncological patients up 79% year-on-year.
Positive Outlook: Management expects continued improvement in the second half, focusing on revenue quality, cash flow, and ongoing operational gains.